4.7 Review

Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy

Journal

PHARMACOLOGY & THERAPEUTICS
Volume 228, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2021.107920

Keywords

Diabetes; Cardiomyopathy; Cardiac dysfunction; Hyperglycemia; Outcome

Funding

  1. Forschungskommission of theMedical Faculty of the Heinrich Heine University [46-2016, 29-2019, 16-2014]
  2. German Research Foundation [LE 940/7-1, PO 2247/2-1, SFB1116]

Ask authors/readers for more resources

Diabetic cardiomyopathy is a common cardiac complication in diabetic patients, characterized by structural and functional changes in the myocardium, leading to a high incidence of heart failure. Current therapeutic options mainly focus on improving the abnormal states of inflammation, apoptosis, reactive oxygen species, and calcium signaling at the cardiomyocyte level.
Diabetes mellitus (DM) is associated with a specific cardiac phenotype characterized by structural and functional alterations. This so-called diabetic cardiomyopathy (DM CM) is clinically relevant as patients with DM show high incidence of heart failure. Mechanistically, several parameters interact on the cardiomyocyte level leading to increased inflammation, apoptosis, reactive oxygen species and altered calcium signaling. This in turn provokes functional myocardial changes that might inter alia play into the worsened clinical outcome in DM patients. Therefore, efficient therapeutic options are urgently needed. This review focuses on mechanistic effects of currently recommended antidiabetic treatment and heart failure therapy for DM CM. (c) 2021 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available